Regulating the Nano-Bio Interface: Converging Electrochemical and Photonic Biosensing for Wearable Diagnostics

Clinical Snapshot

Key Findings

• P Value: Not reported

• Effect Size: Not applicable — no original experimental data or quantitative synthesis presented; performance advantages of convergent platforms over single-modality systems are described qualitatively

• Primary Outcome: Conceptual synthesis of the complementary capabilities of electrochemical and photonic transduction modalities in wearable biosensor platforms, with identification of model systems and emerging convergent device architectures

• Nnt Or Sensitivity: Not reported — no clinical diagnostic accuracy data, sensitivity/specificity values, or patient outcome metrics presented; sensor performance metrics from cited primary studies are referenced descriptively without pooled analysis

• Confidence Interval: Not reported — narrative review with no statistical analysis

Clinical Application

Clinical feasibility is currently limited. The technologies described are largely proof-of-concept. Key barriers to clinical implementation include: lack of large-scale clinical validation studies; absence of regulatory clearance for most described devices; challenges in long-term sensor stability, calibration drift, and biofouling at the skin interface; power supply constraints for continuous dual-modality operation; data integration with existing electronic health record systems; and manufacturing scalability. Near-term clinical translation is most plausible for wound monitoring applications where existing commercial wearable wound sensors provide a regulatory and market precedent. In the Australian context, wearable biosensor technologies of this type would require TGA regulatory approval under the Therapeutic Goods Act 1989 as medical devices (likely Class IIa or higher depending on intended use and risk classification). The PBS does not currently subsidise wearable continuous monitoring beyond established glucose monitoring systems (e.g., continuous glucose monitors listed under the NDSS). The RACGP has expressed interest in digital health and remote monitoring tools, particularly for chronic disease management in rural and remote populations — an area where convergent wearable biosensors could offer significant benefit if validated. The Australian Digital Health Agency's national digital health strategy provides a policy framework supportive of such innovations. Equity considerations are paramount: cost, digital literacy, and connectivity infrastructure in remote and Indigenous communities must be addressed before widespread deployment. No Australian-specific clinical data are referenced in this review. Potentially applicable to patients requiring continuous physiological monitoring across multiple clinical domains, including wound care (particularly chronic wounds and post-surgical monitoring), endocrine disorders requiring hormone monitoring (e.g., cortisol in adrenal insufficiency, glucose in diabetes), sports medicine, occupational health, and remote patient monitoring in aged care. However, all applications remain at research or early prototype stage.

Abstract

The development of wearable biosensors has accelerated due to the combination of nanomaterials, integrative electronics, and miniaturized transduction mechanisms, enabling continuous monitoring of physiological and environmental markers. Electrochemical and photonic modalities have been shown to exhibit complementary capabilities in wearable applications, with each offering distinct advantages in sensitivity, selectivity, miniaturization, and power efficiency. Beyond single-modality functionality, the next generation of wearable diagnostics integrates electrochemical and optical transduction within the same platforms. In this short review, we examine the physical and functional demands of such convergence in wearable systems, highlighting model electrochemical systems, such as textile-integrated wound monitoring and hormone sensors, and how optical modalities provide orthogonal observables of interfacial and biochemical conditions. We further explore new emerging device architectures that leverage electrochemical and optical interrogation to generate robust, information-rich data sets, supporting long-term, real-world deployment of wearable diagnostic technologies for personalized healthcare and continuous monitoring applications.

References

1. 1.Kamat, V., Xu, K., An, H., Du, Y., Weiss, S. M., & Bhansali, S. (2026). Regulating the nano-bio interface: Converging electrochemical and photonic biosensing for wearable diagnostics. Nano Letters. https://doi.org/10.1021/acs.nanolett.6c00860